Introduction: Combined-modality treatment is considered standard of care in the treatment of stage III non-small-cell lung cancer (NSCLC).
This utilitarian perspective continues to be relevant in 2012, but with the introduction of advanced modalities, imaging has recently assumed another and equally important role as a non-invasive means to investigate joint pathology.
More recently, the introduction of dual-modality PET/CT imaging systems in clinical environments has revolutionized the practice of diagnostic imaging.
Viewed as a whole, the data reported here argue against the simple theoretical dichotomy outlined in the Introduction between separate modality-specific timers on one hand, and a single supramodal timer on the other.
Until the introduction of combined modality treatment, less than 5% of patients survived 5 years [ 6].
The introduction of this modality in SpA constitutes the principle advance in imaging over the past two decades.
Commercial adoption of academic ideas for non-invasive imaging is further exemplified by the introduction of dual-modality PET/CT tomographs.
The introduction of combined modality trials will require a very prolonged follow-up to demonstrate improved survival and recognize late onset of chronic toxicity.
The introduction of new imaging modalities or new modality combinations for MP-MRI may lead to better CADx systems.
Its use as a gold standard technique for radiological examination of the SB was justified before the introduction of cross-sectional modalities because of its high negative predictive value and ability to identify even subtle mucosal abnormalities in experienced hands.
